Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis: A Literature Review
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis: A Literature Review
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-05-17
DOI
10.3389/fonc.2019.00397
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2018) P G Casali et al. ANNALS OF ONCOLOGY
- Systematic Review of Clinical Outcomes Following Various Treatment Options for Patients with Extraabdominal Desmoid Tumors
- (2018) Kortnye Smith et al. ANNALS OF SURGICAL ONCOLOGY
- Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways
- (2018) Laura Rosenberg et al. CARCINOGENESIS
- Wnt signaling in development and tissue homeostasis
- (2018) Zachary Steinhart et al. DEVELOPMENT
- Novel intra-genic large deletions of CTNNB1 gene identified in WT desmoid-type fibromatosis
- (2018) Chiara Colombo et al. GENES CHROMOSOMES & CANCER
- Pazopanib therapy for desmoid tumors in adolescent and young adult patients
- (2018) Laura Agresta et al. PEDIATRIC BLOOD & CANCER
- Sorafenib for Advanced and Refractory Desmoid Tumors
- (2018) Mrinal M. Gounder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG)
- (2017) Bernd Kasper et al. EUROPEAN JOURNAL OF CANCER
- Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group
- (2017) Nicolas Penel et al. EUROPEAN JOURNAL OF CANCER
- Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas
- (2017) Hanna Koseła-Paterczyk et al. Expert Review of Anticancer Therapy
- TALENs and CRISPR/Cas9 fuel genetically engineered clinically relevantXenopus tropicalistumor models
- (2017) Thomas Naert et al. GENESIS
- Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis)
- (2017) Shivaani Kummar et al. JOURNAL OF CLINICAL ONCOLOGY
- Genotype-phenotype correlation ofCTNNB1mutations reveals different ß-catenin activity associated with liver tumor progression
- (2016) Sandra Rebouissou et al. HEPATOLOGY
- AKT1andBRAFmutations in pediatric aggressive fibromatosis
- (2016) Cristina Meazza et al. Cancer Medicine
- Time Trends in the Incidence and Treatment of Extra-Abdominal and Abdominal Aggressive Fibromatosis: A Population-Based Study
- (2015) Danique L. M. van Broekhoven et al. ANNALS OF SURGICAL ONCOLOGY
- The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
- (2015) John J. O'Shea et al. Annual Review of Medicine
- Targeting theNotch pathway: A potential therapeutic approach for desmoid tumors
- (2015) Hui Shang et al. CANCER
- Notch signaling: An emerging therapeutic target for cancer treatment
- (2015) Xun Yuan et al. CANCER LETTERS
- Sporadic extra abdominal wall desmoid-type fibromatosis: Surgical resection can be safely limited to a minority of patients
- (2015) C. Colombo et al. EUROPEAN JOURNAL OF CANCER
- Near universal detection of alterations inCTNNB1and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis
- (2015) Aimee M. Crago et al. GENES CHROMOSOMES & CANCER
- Constitutive activation of STAT3 in breast cancer cells: A review
- (2015) Kasturi Banerjee et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting Notch, Hedgehog and Wnt pathways in cancer stem cells: clinical update
- (2015) Naoko Takebe et al. Nature Reviews Clinical Oncology
- Treatment of Aggressive Pelvic Fibromatosis With Interferon
- (2015) Femke Ariën et al. OBSTETRICS AND GYNECOLOGY
- Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies
- (2015) Damon R. Reed et al. Cancer Medicine
- Targeting Stem Cell Behavior in Desmoid Tumors (Aggressive Fibromatosis) by Inhibiting Hedgehog Signaling
- (2015) Ronak Ghanbari-Azarnier et al. NEOPLASIA
- Prognostic Value of CTNNB1 Gene Mutation in Primary Sporadic Aggressive Fibromatosis
- (2014) Danique L. M. van Broekhoven et al. ANNALS OF SURGICAL ONCOLOGY
- Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis
- (2014) D. L. M. van Broekhoven et al. BRITISH JOURNAL OF SURGERY
- Percutaneous Image-Guided Cryoablation in Inoperable Extra-abdominal Desmoid Tumors: A Study of Tolerability and Efficacy
- (2014) M. Havez et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- Wnt–Notch signalling crosstalk in development and disease
- (2014) Giovanna M. Collu et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral -Secretase Inhibitor PF-03084014
- (2014) W. A. Messersmith et al. CLINICAL CANCER RESEARCH
- A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis
- (2014) Jae-Cheol Jo et al. INVESTIGATIONAL NEW DRUGS
- The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer
- (2014) Jennifer Bishop et al. Cancers
- A Prognostic Nomogram for Prediction of Recurrence in Desmoid Fibromatosis
- (2013) Aimeé M. Crago et al. ANNALS OF SURGERY
- Spontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought
- (2013) Sylvie Bonvalot et al. ANNALS OF SURGICAL ONCOLOGY
- CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence
- (2013) Chiara Colombo et al. CANCER
- Complex Reconstruction of Desmoid Tumor Resections Does Not Increase Desmoid Tumor Recurrence
- (2013) Patrick B. Garvey et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- The mechanisms of Hedgehog signalling and its roles in development and disease
- (2013) James Briscoe et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- -Catenin Mutation Status and Outcomes in Sporadic Desmoid Tumors
- (2013) J. T. Mullen et al. ONCOLOGIST
- Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study
- (2013) Stephen X. Skapek et al. PEDIATRIC BLOOD & CANCER
- Targeting Notch signaling pathway in cancer: Clinical development advances and challenges
- (2013) Naoko Takebe et al. PHARMACOLOGY & THERAPEUTICS
- Triparanol suppresses human tumor growth in vitro and in vivo
- (2012) Xinyu Bi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Signal transduction pathway analysis in desmoid-type fibromatosis: Transforming growth factor-β, COX2 and sex steroid receptors
- (2012) Nicholas A. Mignemi et al. CANCER SCIENCE
- Molecular Pathways: Context-Dependent Approaches to Notch Targeting as Cancer Therapy
- (2012) A. M. Egloff et al. CLINICAL CANCER RESEARCH
- Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases
- (2012) Justin M.M. Cates et al. HUMAN PATHOLOGY
- Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors
- (2012) Ian Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
- (2012) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics
- (2012) Sophie Le Guellec et al. MODERN PATHOLOGY
- TGFβ signalling in context
- (2012) Joan Massagué NATURE REVIEWS MOLECULAR CELL BIOLOGY
- A High Throughput Screen Identifies Nefopam as Targeting Cell Proliferation in β-Catenin Driven Neoplastic and Reactive Fibroproliferative Disorders
- (2012) Raymond Poon et al. PLoS One
- Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG)
- (2011) D. Garbay et al. ANNALS OF ONCOLOGY
- Colorectal cancers choosing sides
- (2011) Cristina Albuquerque et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Mesenchymal Stromal Cell Mutations and Wound Healing Contribute to the Etiology of Desmoid Tumors
- (2011) A. M. Carothers et al. CANCER RESEARCH
- Akt signalling in health and disease
- (2011) Ingeborg Hers et al. CELLULAR SIGNALLING
- Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review
- (2011) D. Bocale et al. Colorectal Disease
- Abnormalities of the Wnt/β-catenin signalling pathway induce tumour progression in sporadic desmoid tumours: correlation between β-catenin widespread nuclear expression and VEGF overexpression
- (2011) Hiroshi Matono et al. HISTOPATHOLOGY
- Notch3 signalling promotes tumour growth in colorectal cancer
- (2011) Valentina Serafin et al. JOURNAL OF PATHOLOGY
- Advanced aggressive fibromatosis: Effective palliation with chemotherapy
- (2010) Anastasia Constantinidou et al. ACTA ONCOLOGICA
- Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up
- (2010) N. Penel et al. ANNALS OF ONCOLOGY
- Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
- (2010) A Dufresne et al. BRITISH JOURNAL OF CANCER
- High frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management
- (2010) J Dômont et al. BRITISH JOURNAL OF CANCER
- Aggressive Fibromatosis (Desmoid Tumor) Is Derived from Mesenchymal Progenitor Cells
- (2010) C. Wu et al. CANCER RESEARCH
- Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial
- (2010) R. Chugh et al. CLINICAL CANCER RESEARCH
- Potential for functional redundancy in EGF and TGFα signaling in desmoid cells: a cDNA microarray analysis
- (2010) Sylvia H. Trang et al. GROWTH FACTORS
- Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment
- (2009) Marco Fiore et al. ANNALS OF SURGICAL ONCOLOGY
- Dissecting the role of mTOR: Lessons from mTOR inhibitors
- (2009) Ryan J.O. Dowling et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion
- (2009) Frédéric Varnat et al. EMBO Molecular Medicine
- Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas
- (2009) Suzanne George et al. JOURNAL OF CLINICAL ONCOLOGY
- Desmoid cell motility is induced in vitro by rhEGF
- (2009) David E. Joyner et al. JOURNAL OF ORTHOPAEDIC RESEARCH
- Early experience with percutaneous cryoablation of extra-abdominal desmoid tumors
- (2009) Jennifer L. Kujak et al. SKELETAL RADIOLOGY
- Specific Mutations in the β-Catenin Gene (CTNNB1) Correlate with Local Recurrence in Sporadic Desmoid Tumors
- (2008) Alexander J.F. Lazar et al. AMERICAN JOURNAL OF PATHOLOGY
- Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases
- (2008) M. C. Heinrich et al. CLINICAL CANCER RESEARCH
- The role of APC and beta-catenin in the aetiology of aggressive fibromatosis (desmoid tumors)
- (2008) D.J. Lips et al. EJSO
- Correlation between β-catenin widespread nuclear expression and matrix metalloproteinase-7 overexpression in sporadic desmoid tumors
- (2008) Hiroshi Matono et al. HUMAN PATHOLOGY
- The role of PTEN signaling perturbations in cancer and in targeted therapy
- (2008) M Keniry et al. ONCOGENE
- Toremifene decreases type I, type II and increases type III receptors in desmoid and fibroma and inhibits TGFbeta1 binding in desmoid fibroblasts
- (2007) Giordano Stabellini et al. BIOMEDICINE & PHARMACOTHERAPY
- Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients
- (2007) S. Bonvalot et al. EJSO
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started